February 9th 2022
The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.
January 25th 2022
The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod cell therapy in solid tumors.
January 17th 2022
The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod technology in solid tumors.
January 15th 2022
Cedrik Britten, MD, chief medical officer, Immatics, discussed the advantages of IMA203 over other cell therapies.
January 8th 2022
The hematologist/oncologist from Mayo Clinic discussed the growing presence of CAR T-cell therapies in lung cancer and melanoma.
December 12th 2021
The oncologist from Abramson Cancer Center, Penn Medicine discussed the initial results of the phase 1 trial of CT-0508 in HER2-overexpressing solid tumors.
December 9th 2021
The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in common cancers and its use as a biomarker.
Cedrik Britten, MD, chief medical officer, Immatics discussed data on IMA203 presented at SITC 2021.
December 3rd 2021
The hematologist/oncologist from Mayo Clinic discussed the BASECAMP study and how it will inform future studies assessing Tmod technology.
November 28th 2021
CRISPR Therapeutics presented positive data on 2 preclinical programs at the 2021 SITC meeting.